These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 24917890)

  • 1. Efficacy and safety of vildagliptin, Saxagliptin or Sitagliptin as add-on therapy in Chinese patients with type 2 diabetes inadequately controlled with dual combination of traditional oral hypoglycemic agents.
    Li CJ; Liu XJ; Bai L; Yu Q; Zhang QM; Yu P; Yu DM
    Diabetol Metab Syndr; 2014; 6():69. PubMed ID: 24917890
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety comparison of add-on therapy with liraglutide, saxagliptin and vildagliptin, all in combination with current conventional oral hypoglycemic agents therapy in poorly controlled Chinese type 2 diabetes.
    Li CJ; Yu Q; Yu P; Zhang QM; Ding M; Liu XJ; Yu DM
    Exp Clin Endocrinol Diabetes; 2014 Sep; 122(8):469-76. PubMed ID: 24838155
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of vildagliptin, sitagliptin, and linagliptin as add-on therapy in Chinese patients with T2DM inadequately controlled with dual combination of insulin and traditional oral hypoglycemic agent.
    Tang YZ; Wang G; Jiang ZH; Yan TT; Chen YJ; Yang M; Meng LL; Zhu YJ; Li CG; Li Z; Yu P; Ni CL
    Diabetol Metab Syndr; 2015; 7():91. PubMed ID: 26500706
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vildagliptin efficacy in combination with metformin among Jordanian patients with type 2 diabetes mellitus inadequately controlled with metformin.
    Al Omari M; Khader Y; Dauod AS; Beni Yonis OA; Khassawneh AH
    J Drug Assess; 2016; 5(1):29-33. PubMed ID: 27994943
    [No Abstract]   [Full Text] [Related]  

  • 5. Randomized, Double-Blind, Phase 3 Trial of Triple Therapy With Dapagliflozin Add-on to Saxagliptin Plus Metformin in Type 2 Diabetes.
    Mathieu C; Ranetti AE; Li D; Ekholm E; Cook W; Hirshberg B; Chen H; Hansen L; Iqbal N
    Diabetes Care; 2015 Nov; 38(11):2009-17. PubMed ID: 26246458
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and short-term side effects of sitagliptin, vildagliptin and saxagliptin in Chinese diabetes: a randomized clinical trial.
    Zhou XJ; Ding L; Liu JX; Su LQ; Dong JJ; Liao L
    Endocr Connect; 2019 Apr; 8(4):318-325. PubMed ID: 30822272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy.
    Ferrannini E; Fonseca V; Zinman B; Matthews D; Ahrén B; Byiers S; Shao Q; Dejager S
    Diabetes Obes Metab; 2009 Feb; 11(2):157-66. PubMed ID: 19125777
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
    Hermansen K; Kipnes M; Luo E; Fanurik D; Khatami H; Stein P;
    Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Saxagliptin add-on therapy to insulin with or without metformin for type 2 diabetes mellitus: 52-week safety and efficacy.
    Barnett AH; Charbonnel B; Li J; Donovan M; Fleming D; Iqbal N
    Clin Drug Investig; 2013 Oct; 33(10):707-17. PubMed ID: 23949898
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial.
    Ahrén B; Masmiquel L; Kumar H; Sargin M; Karsbøl JD; Jacobsen SH; Chow F
    Lancet Diabetes Endocrinol; 2017 May; 5(5):341-354. PubMed ID: 28385659
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of Vildagliptin as an Add-on to Insulin with or without Metformin in Japanese Patients with Type 2 Diabetes Mellitus: A 12-week, Double-Blind, Randomized Study.
    Hirose T; Suzuki M; Tsumiyama I
    Diabetes Ther; 2015 Dec; 6(4):559-571. PubMed ID: 26620049
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety profile of sitagliptin, vildagliptin, and metformin in newly diagnosed type 2 diabetic subjects.
    Elhini SH; Hussien AK; Omran AAE; Elsayed AA; Saeed H
    Clin Exp Pharmacol Physiol; 2021 Dec; 48(12):1589-1602. PubMed ID: 34333803
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Randomized Controlled Trial of Vildagliptin Versus Alogliptin: Effective Switch From Sitagliptin in Patients With Type 2 Diabetes.
    Shigematsu E; Yamakawa T; Oba MS; Suzuki J; Nagakura J; Kadonosono K; Terauchi Y
    J Clin Med Res; 2017 Jul; 9(7):567-572. PubMed ID: 28611856
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dipeptidyl Peptidase-4 inhibitors use in type II diabetic patients in a tertiary hospital.
    Mak WY; Nagarajah JR; Abdul Halim H; Ramadas A; Mohd Pauzi Z; Pee LT; Jagan N
    J Pharm Policy Pract; 2020; 13():34. PubMed ID: 32566235
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized controlled trial of the efficacy and safety of twice-daily saxagliptin plus metformin combination therapy in patients with type 2 diabetes and inadequate glycemic control on metformin monotherapy.
    White JL; Buchanan P; Li J; Frederich R
    BMC Endocr Disord; 2014 Feb; 14():17. PubMed ID: 24565221
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of vildagliptin-metformin and glimepiride-metformin treatments in type 2 diabetic patients.
    Jeon HJ; Oh TK
    Diabetes Metab J; 2011 Oct; 35(5):529-35. PubMed ID: 22111045
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vildagliptin: a review of its use in type 2 diabetes mellitus.
    Keating GM
    Drugs; 2010 Nov; 70(16):2089-112. PubMed ID: 20964454
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin: a 24-week, randomized, double-blind study.
    Bolli G; Dotta F; Rochotte E; Cohen SE
    Diabetes Obes Metab; 2008 Jan; 10(1):82-90. PubMed ID: 18034842
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions.
    Scheen AJ
    Clin Pharmacokinet; 2010 Sep; 49(9):573-88. PubMed ID: 20690781
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes treated with saxagliptin, sitagliptin, or vildagliptin.
    Tatosian DA; Guo Y; Schaeffer AK; Gaibu N; Popa S; Stoch A; Langdon RB; Kauh EA
    Diabetes Ther; 2013 Dec; 4(2):431-42. PubMed ID: 24163113
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.